Nutrition economic evaluation of a probiotic in the prevention of antibiotic-associated diarrhea

Frontiers in Pharmacology

Volumn 5 FEB, Issue , 2014, Pages

  Lenoir Wijnkoop, Irene ^a,b   Nuijten, Mark J C ^c   Craig, Joyce ^d   Butler, Christopher C ^e  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Scientific Affairs   (France)

^c Ars Accessus Medica   (Netherlands)

^d UNIVERSITY OF YORK   (United Kingdom)

^e CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Antibiotic associated diarrhea; Clostridium difficile; Cost effectiveness; Hospitalized elderly; Nutrition economics; Probiotics

Indexed keywords

LACTOBACILLUS PARACASEI EXTRACT; METRONIDAZOLE; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

AGED; ANTIBIOTIC ASSOCIATED DIARRHEA; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; ECONOMIC EVALUATION; FERMENTED MILK; HEALTH CARE COST; HUMAN; INCIDENCE; INTERVENTION STUDY; LACTOBACILLUS PARACASEI; MILK; MORTALITY; NUTRITIONAL ASSESSMENT; PRACTICE GUIDELINE; PROBABILITY; RECURRENT INFECTION; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; VERY ELDERLY;

EID: 84895547914     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00013     Document Type: Article

References (59)

1. Allen, S. J., Martine, E. G., Gregori, G. V., and Dans, L. F. (2010). Probiotics for treating acute infectious diarrhoea (Review). Cochrane Database Syst. Rev. 10:CD003048. doi: 10.1002/14651858.CD003048.pub3.
2. Allen, S. J., Wareham, K., Wang, D., Bradley, C., Hutchings, H., Harris, W., et al. (2013). Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 382, 1249-1257. doi: 10.1016/S0140-6736(13)61218-0.
3. Barbut, F., Gariazzo, B., Bonne, L., Lalande, V., Burghoffer, B., Luiuz, R., et al. (2007). Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004. Infect. Control Hosp. Epidemiol. 28, 131-139. doi: 10.1086/511794.
4. Barbut, F., Jones, G., and Eckert, C. (2011). Epidemiology and control of Clostridium difficile infections in healthcare settings: an update. Curr. Opin. Infect. Dis. 24, 370-376. doi: 10.1097/QCO.0b013e32834748e5.
5. Bartlett, J. G., and Gerding, D. N. (2008). Clinical recognition and diagnosis of Clostridium difficile infection. Clin. Infect. Dis. 46, S12-S18. doi: 10.1086/521863.
6. Bauer, M. P., Notermans, D. W., van Benthem, B. H., Brazier, J. S., Wilcox, M. H., Rupnik, M., et al. (2011). Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377, 63-73. doi: 10.1016/S0140-6736(10)61266-4.
7. Benson, L., Song, X., Campos, J., and Singh, N. (2007). Changing epidemiology of Clostridium difficile-associated disease in children. Infect. Control Hosp. Epidemiol. 28, 1233-1235. doi: 10.1086/520732.
8. Bergogne-Berezin, E. (2000). Treatment and prevention of antibiotic associated diarrhoea. Int. J. Antimicrob. Agents 16, 521-526. doi: 10.1016/S0924-8579(00)00293-4.
9. Bouza, E., Dryden, M., Mohammed, R., Peppe, J., Chasan-Taber, S., Donovan, J., et al. (2008). Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile associated diarrhoea. Clin. Microbiol. Infect. 14(Suppl. 7), S103-S104. doi: 10.1111/j.1469-0691.2008.02006.x.
10. British National Formulary. (2009). BMJ Group, RCPCH Publications Ltd, and the Royal Pharmaceutical Society of Great Britain. Available online at: http://www.bnf.org/bnf/index.htm.
11. Butler, C. C., Duncan, D., and Hood, K. (2012). Does taking probiotics routinely with antibiotics prevent antibiotic associated diarrhoea? BMJ 344:e682. doi: 10.1136/bmj.e682.
12. Campbell, R. J., Giljahn, L., Machesky, K., Cibulskas-White, K., Lane, L. M., Porte, K., et al. (2009). Clostridium difficile infection in Ohio hospitals and nursing homes during 2006. Infect. Control Hosp. Epidemiol. 30, 526-533. doi: 10.1086/597507.
13. Cartman, S. T., Heap, J. T., Kuehne, S. A., Cockayne, A., and Minton, N. P. (2010). The emergence of 'hypervirulence' in Clostridium difficile. Int. J. Med. Microbiol. 300, 387-395. doi: 10.1016/j.ijmm.2010.04.008.
14. Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., et al. (2010). Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31, 431-455. doi: 10.1086/651706.
15. Cornely, O. A. (2012). Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? Clin. Microbiol. Infect. 18(Suppl. 6), 28-35. doi: 10.1111/1469-0691.12012.
16. Crobach, M. J., Dekkers, O. M., Wilcox, M. H., and Kuijper, E. J. (2009). European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDAD). Clin. Microbiol. Infect. 15, 1053-1066. doi: 10.1111/j.1469-0691.2009.03098.x.
17. Daneman, N. (2013). A probiotic trial: tipping the balance of evidence? Lancet 382, 1228-1230. doi: 10.1016/S0140-6736(13)61571-8.
18. Debast, S. B., Bauer, M. P., and Kuijper, E. J. (2014). European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 20(Suppl. 2), 1-26. doi: 10.1111/1469-0691.12418.
19. Department of Health Health Protection Agency. (2008). Clostridium Difficile Infection: How to Deal with the Problem. London: Departement of Health. Available online at: http://www.hpa.org.uk/webc/hpawebfile/hpaweb_c/1232006607827.
20. Department of Health Reference Costs. (2009/10). London: Department of Health. Available online at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123459.
21. Drekonja, D. M., Butler, M., MacDonald, R., Bliss, D., Filice, G. A., Rector, T. S., et al. (2011). Comparative effectiveness of Clostridium difficile treatments. Ann. Intern. Med. 155, 839-847. doi: 10.7326/0003-4819-155-12-201112200-00007.
22. Drummond, M., and McGuire, A. (2001). Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press.
23. Dubberke, E. R., and Wertheimer, A. I. (2009). Review of current literature on the economic burden of Clostridium difficile infection. Infect. Control Hosp. Epidemiol. 30, 57-66. doi: 10.1086/592981.
24. FAO/WHO. (2001). Joint FAO/WHO. Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Available online at: http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf.
25. Fitzpatrick, F., and Barbut, F. (2012). Breaking the cycle of recurrent Clostridium difficile infections. Clin. Microbiol. Infect. 18(Suppl. 6), 2-4. doi: 10.1111/1469-0691.12043.
26. Gerding, D. N., and Gerding, D. N. (2005). Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin. Infect. Dis. 40, 1598-1600. doi: 10.1086/430317.
27. Gerding, D. N., Muto, C. A., and Owens, R. C. Jr. (2008). Treatment of Clostridium difficile infection. Clin. Infect. Dis. 46(suppl. 1), S32-S42. doi: 10.1086/521860.
28. Ghantoji, S. S., Sail, K., Lairson, D. R., DuPont, H. L., and Garey, K. W. (2010). Economic healthcare costs of Clostridium difficile infection: a systematic review. J. Hosp. Infect. 74, 309-318. doi: 10.1016/j.jhin.2009.10.016.
29. Goldenberg, J. Z., Ma, S. S., Saxton, J. D., Martzen, M. R., Vandvik, P. O., Thorlund, K., et al. (2013). Probiotics for the prevention of Clostridium difficile-associated diarrhoea in adults and children. Cochrane Database Syst. Rev. 31:CD006095. doi: 10.1002/14651858.CD006095.pub3.
30. Graul, T., Cain, A. M., and Karpa, K. D. (2009). Lactobacillus and bifidobacteria combinations: a strategy to reduce hospital acquired Clostridium difficile diarrhoea incidence and mortality. Med. Hypotheses 73, 194-198. doi: 10.1016/j.mehy.2009.02.026.
31. Hempel, S., Newberry, S., Ruelaz, A., Wang, Z., Miles, J. N., Suttorp, M. J., et al. (2011). Safety of Probiotics Used to Reduce Risk and Prevent or Treat Disease (Review). Evidence Report/Technology Assessment: Number 200. Rockville, MD: Agency for Healthcare Research and Quality. Available online at: www.ahrq.gov/clinic/tp/probiotictp.htm.
32. Hempel, S., Newberry, S. J., Maher, A. R., Wang, Z., Miles, J. N., Shanman, R., et al. (2012). Probiotics for the prevention and treatment of antibiotic-associated diarrhea-a systematic review and meta-analysis. JAMA 307, 1959-69. doi: 10.1001/jama.2012.3507.
33. Hickson, M., D'Souza, A. L., Muthu, N., Rogers, T. R., Want, S., Rajkumar, C., et al. (2007). Use of probiotic Lactobacillus preparation to prevent diarrhea associated with antibiotics: randomized double blind placebo controlled trial. BMJ 335 80-85. doi: 10.1136/bmj.39231.599815.55.
34. Honda, H., and Dubberke, E. R. (2014). The changing epidemiology of Clostridium difficile infection. Curr.Opin. Gastroenterol. 30, 54-62. doi: 10.1097/MOG.0000000000000018.
35. Jones, A. M., Kuijper, E. J., and Wilcox, M. H. (2013). Clostridium difficile: a European perspective. J. Infect. 66, 115e128. doi: 10.1016/j.jinf.2012.10.019.
36. Kuijper, E. J., Coignard, B., and Tull, P. (2006). ESCMID study group for Clostridium difficile. Emergence of Clostridium difficile associated disease in North America and Europe. Clin. Microbiol. Infect. 12, 2-18. doi: 10.1111/j.1469-0691.2006.01580.x.
37. Kyne, L. (2010). Clostridium difficile-beyond antibiotics. N. Engl. J. Med. 362, 264-265. doi: 10.1056/NEJMe0910055.
38. Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., et al. (2005). A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhoea with high morbidity and mortality. N. Engl. J. Med. 353, 2442-2449. doi: 10.1056/NEJMoa051639.
39. Louie, T., Gerson, M., Grimard, D., Johnson, S., Poirier, A., and Weiss, K. (2007). "Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhoea (CDAD) [abstract K-4259]," in Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC: ASM Press).
40. Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., et al. (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364, 422-431. doi: 10.1056/NEJMoa0910812.
41. Lowy, I., Molrine, D. C., Leave, B. A., Blair, B. M., Baxter, R., Gerding, D. N., et al. (2010). Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362, 197-205. doi: 10.1056/NEJMoa0907635.
42. Maziade, P.-J., Andriessen, J. A., Pereira, P., Currie, B., and Goldstein, E. J. C. (2013). Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr. Med. Res. Opin. 1-7. doi: 10.1185/03007995.2013.833501.
43. McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C. Jr. Kazakova, S. V., Sambol, S. P., et al. (2005). An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353, 2433-2441. doi: 10.1056/NEJMoa051590.
44. Miller, M. A., Hyland, M., Ofner-Agostini, M., Gourdeau, M., and Ishak, M. (2002). Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect. Control Hosp. Epidemiol. 23, 137-140. doi: 10.1086/502023.
45. National Audit Office. (2004). The management and control of hospital acquired infection in acute NHS trusts in England. National Clostridium difficile Standards Group. Report to the Department of Health. J. Hosp. Infect. 56(Suppl. 1), S1-S38.
46. National Institute for Health and Clinical Excellence. (2008). Guide to the Methods of Technology Appraisal. ISBN: 1-84629-741-9. London: National Institute for Health and Clinical Excellence. Available online at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf.
47. Parkes, G. C., Sanderson, J. D., and Whelan, K. (2009). The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infect. Dis. 9, 237-244. doi: 10.1016/S1473-3099(09)70059-3.
48. Pépin, J., Alary, M.-E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., et al. (2005a). Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 40, 1591-1597. doi: 10.1086/430315.
49. Pépin, J., Valiquette, L., and Cossette, B. (2005b). Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173:1037-1042. doi: 10.1503/cmaj.050978.
50. Pépin, J., Routhier, S., Gagnon, S., and Brazeau, I. (2006). Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin. Infect. Dis. 42, 758-64. doi: 10.1086/501126.
51. PSSRU Unit Costs of Health and Social Care. (2010). Canterbury: Personal Social Services Research Unit, University of Kent. Available online at: http://www.pssru.ac.uk/project-pages/unit-costs/2010/.
52. Radavelli-Bagatini, S., Zhu, K., Lewis, J. R., Dhaliwal, S. S., and Prince, R. L. (2013). Association of dairy intake with body composition and physical function in older community-dwelling women. J. Acad. Nutr. Diet. S2212-S2672(13)00645-X. doi: 10.1016/j.jand.2013.05.019.
53. Ritchie, M. L., and Romanuk, T. N. (2012). A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE 7:e34938. doi: 10.1371/journal.pone.0034938.
54. Shannon-Lowe, J., Matheson, N. J., Cooke, F. J., and Aliyu, S. H. (2010). Prevention and medical management of Clostridium difficile infection. BMJ 340, 641-646. doi: 10.1136/bmj.c1296.
55. Surawicz, C. M. (2005). Antibiotic-asssociated diarrhoea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials? Chemotherapy 51(Suppl. 1), 816-819. doi: 10.1159/000081993.
56. Videlock, E. J., and Cremonini, F. (2012). Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment. Pharmacol. Ther. 35, 1355-1369. doi: 10.1111/j.1365-2036.2012.05104.x.
57. Vonberg, R. P., Reichardt, C., Behnke, M., Schwab, F., Zindler, S., and Gastmeier, P. (2008). Costs of nosocomial Clostridium difficile-associated diarrhoea. J. Hosp. Infect. 70, 15-20. doi: 10.1016/j.jhin.2008.05.004.
58. Wiegand, P. N., Nathwani, D., Wilcox, M. H., Stephens, J., Shelbaya, A., and Haider, S. (2012). Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J. Hosp. Infect. 81, 1-14. doi: 10.1016/j.jhin.2012.02.004.
59. Zar, F. A., Bakkanagari, S. R., Moorthi, K. M., and Davis, M. B. (2007). A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhoea, stratified by disease severity. Clin. Infect. Dis. 45, 302-307. doi: 10.1086/519265.